Houston digital health platform Koda closes $7 million funding round

fresh funding

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

From Your Site Articles
Koda Health has integrated its advance care planning platform with Epic Systems. Photo via kodahealthcare.com.

Houston palliative care company integrates with Epic platforms

epic scale

Patients and medical teams using MyChart and other Epic Systems' software will now be able to access Houston-based Koda Health's AI-enhanced end-of-life planning platform.

The Houston-based palliative care company, which was born out of the TMC's Biodesign Fellowship, has integrated its advance care planning platform with Epic, one of the most widely used electronic health record (EHR) systems in the U.S., according to a news release.

Epic estimates that more than 325 million patients have a current electronic record in its systems.

“This is a significant milestone for our mission to make advance care planning scalable, meaningful, and seamless,” Tatiana Fofanova, CEO and co-founder of Koda Health, said in the release. “By integrating into systems already used by care teams, we help eliminate friction and ensure that care delivery honors what patients truly want—especially during serious illness and at the end of life.”

The partnership will streamline processes for both patients and clinicians. Users will be able to drop advance care plans directly into the Epic charts, which will be accessible through MyChart for patients and proxies and through Epic Hyperspace/Hyperdrive for care teams. Doctors can also initiate and manage advance care plans through a simple Epic order for patients.

According to Koda Health, its platform saves an average of $10,000 to $15,000 per patient. Roughly 85 percent of users complete advance care plan documents when using the platform, which is four times the national average.

“We developed Koda to give providers the time, training, and tools to guide these critical conversations," Dr. Desh Mohan, co-founder and chief medical officer at Koda Health, added in the statement. "Our integration now makes it possible to operationalize ACP at scale—aligned with value-based care goals and clinical reality.”

The company announced a partnership with Dallas-based Guidehealth, which integrates into primary care workflows and allows providers to identify high-risk patients, coordinate care and reduce administrative burden. Guidehealth works with more than 500,000 patients

Koda Health was founded in 2020 and closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. The company also added Kidney Action Planning to its suite of services in 2024.

Jessica Traver Ingram, CEO and co-founder of IntuiTap, joins the Houston Innovators Podcast to share her company's latest milestone. Photo courtesy of IntuiTap

With FDA approval, Houston health tech company prepares nationwide deployment

Houston innovators podcast episode 232

Jessica Traver Ingram has been captivated by the intersection of physics and health care for most of her life, and that passion led her to contributing to the establishment of the Texas Medical Center's Biodesign Fellowship. After helping make the program a reality, Traver Ingram then participated in it as a fellow.

The program selects fellows and then lets them explore the TMC's member institutions to find ways to innovate within unmet clinical needs, and the inefficiency and challenges with placing epidurals and lumbar punctures caught Traver Ingram and her cohort's eye. The process relies completely on the health care practitioner's ability to feel the spine with their fingers to make the injection.

"We kept watching the inefficiencies of these procedures, and everyone was like, 'you're right, we don't really know why we do it this way,'" Traver Ingram says on the Houston Innovators Podcast. "It's really cool to be outsiders watching and observing, because you just see things other people don't see — and that's in any industry."

With that, IntuiTap was born. Traver Ingram describes its tool, the VerTouch, as a "stud finder for the spine." After years of growing the company, she can also now call it FDA-approved.


"FDA clearance allows us to market the device in the United States, so we are entering the commercial launch stage of the company, which is really exciting," Traver Ingram says. "We plan to have these devices available in hospitals across the country within the year."

First up is what Traver Ingram calls a soft launch. The company is picking five institutions that want to be centers of excellence for the device and doing trial launches there before entering into a greater, nationwide rollout.

"It's just crazy that what started as just an idea on paper is now FDA approved and commercially ready and something that patients can see in hospitals this year," Traver Ingram says.

And the timing is important, she explains, adding that where the health care industry seems to be at as a whole is primed for innovation like IntuiTap.

"There's a lot of really exciting developments happening in health care right now," Traver Ingram says. "I feel like we're really at a tipping point for innovation and we're going to see some really big leaps in the next couple of years.

"One of the exciting trends I think that we're seeing is a shift away from blind procedures or procedures that are seen as an art requiring a significant amount of skills toward more science-based, safer, consistent, and repeatable procedures," she continues. "We fit really well into that category, so I'm glad that we're seeing that shift."

NeuraStasis, which originated out of the TMC Biodesign program, is launching its latest study in Houston. Photo via Getty Images

Health tech startup launches Houston study improve stroke patients recovery

now enrolling

A Houston-born company is enrolling patients in a study to test the efficacy of nerve stimulation to improve outcomes for stroke survivors.

Dr. Kirt Gill and Joe Upchurch founded NeuraStasis in 2021 as part of the TMC Biodesign fellowship program.

“The idea for the company manifested during that year because both Joe and I had experiences with stroke survivors in our own lives,” Gill tells InnovationMap. It began for Gill when his former college roommate had a stroke in his twenties.

“It’s a very unpredictable, sudden disease with ramifications not just for my best friend but for everyone in his life. I saw what it did to his family and caregivers and it's one of those things that doesn't have as many solutions for people to continue recovery and to prevent damage and that's an area that I wanted to focus myself on in my career,” Gill explains.

Gill and Upchurch arrived at the trigeminal and vagus nerves as a potential key to helping stroke patients. Gill says that there is a growing amount of academic literature that talks about the efficacy of stimulating those nerves. The co-founders met Dr. Sean Savitz, the director of the UTHealth Institute for Stroke and Cerebrovascular Diseases, during their fellowship. He is now their principal investigator for their clinical feasibility study, located at his facility.

The treatment is targeted for patients who have suffered an ischemic stroke, meaning that it’s caused by a blockage of blood flow to the brain.

“Rehabilitation after a stroke is intended to help the brain develop new networks to compensate for permanently damaged areas,” Gill says. “But the recovery process typically slows to essentially a standstill or plateau by three to six months after that stroke. The result is that the majority of stroke survivors, around 7.6 million in the US alone, live with a form of disability that prevents complete independence afterwards.”

NeuraStasis’ technology is intended to help patients who are past that window. They accomplish that with a non-invasive brain-stimulation device that targets the trigeminal and vagus nerves.

“Think of it kind of like a wearable headset that enables stimulation to be delivered, paired to survivors going through rehabilitation action. So the goal here is to help reinforce and rewire networks as they're performing specific tasks that they're looking to improve upon,” Gill explains.

The study, which hopes to enroll around 25 subjects, is intended to help people with residual arm and hand deficits six months or more after their ischemic stroke. The patients enrolled will receive nerve stimulation three times a week for six weeks. It’s in this window that Gill says he hopes to see meaningful improvement in patients’ upper extremity deficits.

Though NeuraStasis currently boasts just its two co-founders as full-time employees, the company is seeing healthy growth. It was selected for a $1.1 million award from the National Institutes of Health through its Blueprint MedTech program. The award was funded by the National Institute of Neurological Disorders and Stroke. The funding furthers NeuraStasis’ work for two years, and supports product development for work on acute stroke and for another product that will aid in emergency situations.

Gill says that he believes “Houston has been tailor-made for medical healthcare-focused innovation.”

NeuraStasis, he continues, has benefited greatly from its advisors and mentors from throughout the TMC, as well as the engineering talent from Rice, University of Houston and Texas A&M. And the entrepreneur says that he hopes that Houston will benefit as much from NeuraStasis’ technology as the company has from its hometown.

“I know that there are people within the community that could benefit from our device,” he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston neighbor named richest small town in Texas for 2025

Ranking It

Affluent Houston neighbor Bellaire is cashing in as the richest small town in Texas for 2025, according to new study from GoBankingRates.

The report, "The Richest Small Town in Every State," used data from the U.S. Census Bureau's American Community Survey to determine the 50 richest small towns in America based on their median household income.

Of course, Houstonians realize that describing Bellaire as a "small town" is a bit of misnomer. Located less than 10 miles from downtown and fully surrounded by the City of Houston, Bellaire is a wealthy enclave that boasts a population of just over 17,000 residents. These affluent citizens earn a median $236,311 in income every year, which GoBankingRates says is the 11th highest household median income out of all 50 cities included in the report.

The average home in this city is worth over $1.12 million, but Bellaire's lavish residential reputation often attracts properties with multimillion-dollar price tags.

Bellaire also earned a shining 81 livability score for its top quality schools, health and safety, commute times, and more. The livability index, provided by Toronto, Canada-based data analytics and real estate platform AreaVibes, said Bellaire has "an abundance of exceptional local amenities."

"Among these are conveniently located grocery stores, charming coffee shops, diverse dining options and plenty of spacious parks," AreaVibes said. "These local amenities contribute significantly to its overall appeal, ensuring that [residents'] daily needs are met and offering ample opportunities for leisure and recreation."

Earlier in 2025, GoBankingRates ranked Bellaire as the No. 23 wealthiest suburb in America, and it's no stranger to being named on similar lists comparing the richest American cities.

---

This article originally appeared on CultureMap.com.

How a Houston startup is taking on corrosion, a costly climate threat

now streaming

Corrosion is not something most people think about, but for Houston's industrial backbone pipelines, refineries, chemical plants, and water infrastructure, it is a silent and costly threat. Replacing damaged steel and overusing chemicals adds hundreds of millions of tons of carbon emissions every year. Despite the scale of the problem, corrosion detection has barely changed in decades.

In a recent episode of the Energy Tech Startups Podcast, Anwar Sadek, founder and CEO of Corrolytics, explained why the traditional approach is not working and how his team is delivering real-time visibility into one of the most overlooked challenges in the energy transition.

From Lab Insight to Industrial Breakthrough

Anwar began as a researcher studying how metals degrade and how microbes accelerate corrosion. He quickly noticed a major gap. Companies could detect the presence of microorganisms, but they could not tell whether those microbes were actually causing corrosion or how quickly the damage was happening. Most tests required shipping samples to a lab and waiting months for results, long after conditions inside the asset had changed.

That gap inspired Corrolytics' breakthrough. The company developed a portable, real-time electrochemical test that measures microbial corrosion activity directly from fluid samples. No invasive probes. No complex lab work. Just the immediate data operators can act on.

“It is like switching from film to digital photography,” Anwar says. “What used to take months now takes a couple of hours.”

Why Corrosion Matters in Houston's Energy Transition

Houston's energy transition is a blend of innovation and practicality. While the world builds new low-carbon systems, the region still depends on existing industrial infrastructure. Keeping those assets safe, efficient, and emission-conscious is essential.

This is where Corrolytics fits in. Every leak prevented, every pipeline protected, and every unnecessary gallon of biocide avoided reduces emissions and improves operational safety. The company is already seeing interest across oil and gas, petrochemicals, water and wastewater treatment, HVAC, industrial cooling, and biofuels. If fluids move through metal, microbial corrosion can occur, and Corrolytics can detect it.

Because microbes evolve quickly, slow testing methods simply cannot keep up. “By the time a company gets lab results, the environment has changed completely,” Anwar explains. “You cannot manage what you cannot measure.”

A Scientist Steps Into the CEO Role

Anwar did not plan to become a CEO. But through the National Science Foundation's ICorps program, he interviewed more than 300 industry stakeholders. Over 95 percent cited microbial corrosion as a major issue with no effective tool to address it. That validation pushed him to transform his research into a product.

Since then, Corrolytics has moved from prototype to real-world pilots in Brazil and Houston, with early partners already using the technology and some preparing to invest. Along the way, Anwar learned to lead teams, speak the language of industry, and guide the company through challenges. “When things go wrong, and they do, it is the CEO's job to steady the team,” he says.

Why Houston

Relocating to Houston accelerated everything. Customers, partners, advisors, and manufacturing talent are all here. For industrial and energy tech startups, Houston offers an ecosystem built for scale.

What's Next

Corrolytics is preparing for broader pilots, commercial partnerships, and team growth as it continues its fundraising efforts. For anyone focused on asset integrity, emissions reduction, or industrial innovation, this is a company to watch.

Listen to the full conversation with Anwar Sadek on the Energy Tech Startups Podcast to learn more:

---

Energy Tech Startups Podcast is hosted by Jason Ethier and Nada Ahmed. It delves into Houston's pivotal role in the energy transition, spotlighting entrepreneurs and industry leaders shaping a low-carbon future.

This article originally appeared on our sister site, EnergyCapitalHTX.com.

These 50+ Houston scientists rank among world’s most cited

science stars

Fifty-one scientists and professors from Houston-area universities and institutions were named among the most cited in the world for their research in medicine, materials sciences and an array of other fields.

The Clarivate Highly Cited Researchers considers researchers who have authored multiple "Highly Cited Papers" that rank in the top 1percent by citations for their fields in the Web of Science Core Collection. The final list is then determined by other quantitative and qualitative measures by Clarivate's judges to recognize "researchers whose exceptional and community-wide contributions shape the future of science, technology and academia globally."

This year, 6,868 individual researchers from 60 different countries were named to the list. About 38 percent of the researchers are based in the U.S., with China following in second place at about 20 percent.

However, the Chinese Academy of Sciences brought in the most entries, with 258 researchers recognized. Harvard University with 170 researchers and Stanford University with 141 rounded out the top 3.

Looking more locally, the University of Texas at Austin landed among the top 50 institutions for the first time this year, tying for 46th place with the Mayo Clinic and University of Minnesota Twin Cities, each with 27 researchers recognized.

Houston once again had a strong showing on the list, with MD Anderson leading the pack. Below is a list of the Houston-area highly cited researchers and their fields.

UT MD Anderson Cancer Center

  • Ajani Jaffer (Cross-Field)
  • James P. Allison (Cross-Field)
  • Maria E. Cabanillas (Cross-Field)
  • Boyi Gan (Molecular Biology and Genetics)
  • Maura L. Gillison (Cross-Field)
  • David Hong (Cross-Field)
  • Scott E. Kopetz (Clinical Medicine)
  • Pranavi Koppula (Cross-Field)
  • Guang Lei (Cross-Field)
  • Sattva S. Neelapu (Cross-Field)
  • Padmanee Sharma (Molecular Biology and Genetics)
  • Vivek Subbiah (Clinical Medicine)
  • Jennifer A. Wargo (Molecular Biology and Genetics)
  • William G. Wierda (Clinical Medicine)
  • Ignacio I. Wistuba (Clinical Medicine)
  • Yilei Zhang (Cross-Field)
  • Li Zhuang (Cross-Field)

Rice University

  • Pulickel M. Ajayan (Materials Science)
  • Pedro J. J. Alvarez (Environment and Ecology)
  • Neva C. Durand (Cross-Field)
  • Menachem Elimelech (Chemistry and Environment and Ecology)
  • Zhiwei Fang (Cross-Field)
  • Naomi J. Halas (Cross-Field)
  • Jun Lou (Materials Science)
  • Aditya D. Mohite (Cross-Field)
  • Peter Nordlander (Cross-Field)
  • Andreas S. Tolias (Cross-Field)
  • James M. Tour (Cross-Field)
  • Robert Vajtai (Cross-Field)
  • Haotian Wang (Chemistry and Materials Science)
  • Zhen-Yu Wu (Cross-Field)

Baylor College of Medicine

  • Nadim J. Ajami (Cross-Field)
  • Biykem Bozkurt (Clinical Medicine)
  • Hashem B. El-Serag (Clinical Medicine)
  • Matthew J. Ellis (Cross-Field)
  • Richard A. Gibbs (Cross-Field)
  • Peter H. Jones (Pharmacology and Toxicology)
  • Sanjay J. Mathew (Cross-Field)
  • Joseph F. Petrosino (Cross-Field)
  • Fritz J. Sedlazeck (Biology and Biochemistry)
  • James Versalovic (Cross-Field)

University of Houston

  • Zhifeng Ren (Cross-Field)
  • Yan Yao (Cross-Field)
  • Yufeng Zhao (Cross-Field)
  • UT Health Science Center Houston
  • Hongfang Liu (Cross-Field)
  • Louise D. McCullough (Cross-Field)
  • Claudio Soto (Cross-Field)

UTMB Galveston

  • Erez Lieberman Aiden (Cross-Field)
  • Pei-Yong Shi (Cross-Field)

Houston Methodist

  • Eamonn M. M. Quigley (Cross-Field)
View All Listings